ATE400275T1 - Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus - Google Patents

Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus

Info

Publication number
ATE400275T1
ATE400275T1 AT03791769T AT03791769T ATE400275T1 AT E400275 T1 ATE400275 T1 AT E400275T1 AT 03791769 T AT03791769 T AT 03791769T AT 03791769 T AT03791769 T AT 03791769T AT E400275 T1 ATE400275 T1 AT E400275T1
Authority
AT
Austria
Prior art keywords
adenosine
worst
treatment
receptor antagonists
legs syndrome
Prior art date
Application number
AT03791769T
Other languages
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Akihisa Mori
Dayao Zhao
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE400275(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE400275T1 publication Critical patent/ATE400275T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03791769T 2002-08-30 2003-08-27 Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus ATE400275T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40695502P 2002-08-30 2002-08-30

Publications (1)

Publication Number Publication Date
ATE400275T1 true ATE400275T1 (de) 2008-07-15

Family

ID=31978389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791769T ATE400275T1 (de) 2002-08-30 2003-08-27 Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus

Country Status (16)

Country Link
US (1) US7759355B2 (de)
EP (1) EP1534289B2 (de)
JP (1) JP4498140B2 (de)
KR (1) KR20050058468A (de)
CN (1) CN1671390A (de)
AR (1) AR041116A1 (de)
AT (1) ATE400275T1 (de)
AU (1) AU2003262860A1 (de)
BR (1) BR0313503A (de)
CA (1) CA2496920A1 (de)
DE (1) DE60322067D1 (de)
EA (1) EA008339B1 (de)
ES (1) ES2310258T5 (de)
MX (1) MXPA05001461A (de)
TW (1) TW200410698A (de)
WO (1) WO2004019949A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20070149555A1 (en) * 2004-03-30 2007-06-28 Kyowa Hakko Kogyo Co., Ltd Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
AR080541A1 (es) * 2009-06-26 2012-04-18 Ferring Int Ct Sa Tratamiento para la endometriosis
RU2480469C1 (ru) * 2012-02-03 2013-04-27 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
EP0912174B1 (de) 1996-07-17 2004-04-28 MERCK & CO., INC. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
SE509618C2 (sv) 1997-03-06 1999-02-15 Goeran Blomqvist Farmaceutisk komposition för behandling av s k restless legs
PL343593A1 (en) 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
US5945424A (en) 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
US6346283B1 (en) 1999-03-26 2002-02-12 Ancile Pharmaceuticals Use of valeriana for the treatment of restless leg syndrome and related disorders
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
JP2003523405A (ja) * 2000-02-22 2003-08-05 セレジー カナダ インコーポレイテッド 睡眠改善のための方法および組成物
US6258814B1 (en) 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
ES2716404T3 (es) 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
WO2006053012A2 (en) 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria

Also Published As

Publication number Publication date
ES2310258T5 (es) 2012-05-31
WO2004019949A1 (en) 2004-03-11
EA008339B1 (ru) 2007-04-27
DE60322067D1 (de) 2008-08-21
BR0313503A (pt) 2005-06-21
EP1534289B1 (de) 2008-07-09
CN1671390A (zh) 2005-09-21
US7759355B2 (en) 2010-07-20
AR041116A1 (es) 2005-05-04
AU2003262860A1 (en) 2004-03-19
US20050245545A1 (en) 2005-11-03
KR20050058468A (ko) 2005-06-16
ES2310258T3 (es) 2009-01-01
EP1534289B2 (de) 2012-02-22
TW200410698A (en) 2004-07-01
EA200500427A1 (ru) 2005-08-25
JP2005539050A (ja) 2005-12-22
JP4498140B2 (ja) 2010-07-07
MXPA05001461A (es) 2005-06-03
CA2496920A1 (en) 2004-03-11
EP1534289A1 (de) 2005-06-01

Similar Documents

Publication Publication Date Title
FR19C1072I2 (fr) Derive de 2-acylaminothiazole et son sel
PL374832A1 (pl) Nowe podstawione benzoimidazolowe postacie dawkowe i sposoby ich stosowania
IS8119A (is) Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
ATE490775T1 (de) Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms
EP1692085A4 (de) Inhibierung von fgfr3 und behandlung von multiplem myelom
PL374700A1 (pl) Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
DE60305374T8 (de) Insassenbeinschutzvorrichtung
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DE60317967D1 (de) Umhüllte feste Darreichungsform
EP1636359A4 (de) Verfahren zur schmerzbehandlung
EP1690550A4 (de) Therapeutisches mittel gegen mesotheliom
IL173705A (en) Benzoimideazolone compounds having an activity of 4 h t - 5 agonist receptor and pharmaceutical preparations containing them
DE50308694D1 (de) Bestrahlungsger t
NO20016246D0 (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
PL1692102T3 (pl) Kompozycje i sposoby do wykrywania i leczenia chorób i stanów związanych z receptorami chemokiny
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
DE60322067D1 (de) Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
IS2456B (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60325855D1 (de) Rifampicin zur Behandlung der Angiogenese
DE60307582D1 (de) Insassenbeinschutzvorrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties